• Zimmer Biomet posted Q2 net sales of $2.18 billion, up 4.8% from a year earlier.
• Net earnings rose to $198.3 million; GAAP diluted EPS climbed 33.8% to $1.03.
• Operating cash flow totaled $447.9 million, producing free cash flow of $308.3 million.
• Raised 2026 outlook for reported revenue growth to 3.9%-4.9% from 2.5%-4.5%; lifted adjusted diluted EPS to $8.47-$8.59.
• Boosted 2026 share repurchase expectations to as much as $1 billion; CEO Ivan Tornos cited strong first-half results and momentum from innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zimmer Biomet Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-333761), on August 05, 2026, and is solely responsible for the information contained therein.